Gilead Sciences (GILD) 79.02 $GILD
Jim Cramer's 'Mad Money' Recap: Unsafe at Any Price
at The Street - Thu May 01, 7:00PM CDT
Big money managers are once again shifting direction, Cramer says.
Vertex ends hepatitis C investment as sales fall
AP - Thu May 01, 6:27PM CDT
NEW YORK (AP) — Vertex Pharmaceuticals, which reported more than $1 billion in sales of its hepatitis C drug Incivek in 2012, said Thursday it won't invest any more money on research and development of new treatments for the disease.
Final Glance: Biotechnology companies
AP - Thu May 01, 5:07PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
OncoGenex Posts Wider Loss, Beats Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 4:20PM CDT
OncoGenex (OGXI) reported a loss of 59 cents/share in 1Q14, wider than the Zacks Consensus Estimate of a loss of 44 cents and the year-ago loss of 46 cents.
Synageva's Q1 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 4:10PM CDT
Synageva (GEVA) posts narrower-than-expected loss in the first quarter of 2014.
CRL for The Medicines Co.'s Cangrelor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:05PM CDT
The FDA issued a CRL to The Medicines Co.'s (MDCO) NDA for cangrelor.
Midday Glance: Biotechnology companies
AP - Thu May 01, 12:46PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Merck (MRK) Earnings Beat Puts Healthcare ETFs in Focus - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu May 01, 12:34PM CDT
These health care ETFs are in focus thanks to a solid earnings report from Merck (MRK).
United Therapeutics Gains on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 12:10PM CDT
United Therapeutics' (UTHR) first quarter earnings were significantly above expectations.
Wider-than-expected Loss at Alkermes, Revenues Slip - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 10:50AM CDT
Lower revenues primarily led to the wider loss at Alkermes (ALKS).
Watch for Shares of Gilead Sciences (GILD) to Approach Resistance at $80.73
Comtex SmarTrend(R) - Thu May 01, 10:15AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $77.55 today and have reached the first resistance level of $79.61. Analysts will be watching for a cross of the next upside pivot targets of $80.73 and $83.91.
Early Glance: Biotechnology companies
AP - Thu May 01, 10:09AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Strength Seen in Avanir Pharmaceuticals, Inc. (AVNR) as Stock Shoots up 45.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 7:44AM CDT
Avanir Pharmaceuticals, Inc. (AVNR) was a big mover last session, as the company saw its shares surge a whopping 45.6% on the day.
Kors Among 5 Stocks With Superior 3-Year EPS Growth
at Investor's Business Daily - Thu May 01, 7:02AM CDT
Fundamentally sound stocks such as Michael Kors have demonstrated long-term stability. With the market in correction, they're good candidates for a stock watch list. Today's Screen Of The Day is Top Fundamentals, stocks with three-year earnings per...
Beyond Bristol's Big Dividend: 3 Things Investors Need to Know
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 5:30PM CDT
Bristol-Myers ' first-quarter sales appear tepid at best as revenue fell 1% to $3.8 billion, although its juicy dividend of 2.9% has certainly been attractive to income investors.However, there are some encouraging signs that Bristol may be...
Gilead Sciences Rises 2.95% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 30, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $75.49 to a high of $78.67. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $76.80 on volume of 20.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 2.95% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Apr 30, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $75.49 to a high of $78.67. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $76.80 on volume of 20.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Amicus Up on Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 1:32PM CDT
Shares of Amicus Therapeutics (FOLD) shot up 20.7% after it announced positive data from its first phase III study on migalastat HCl monotherapy.
Jim Cramer's 'Mad Money' Recap: Unsafe at Any Price
at The Street - Thu May 01, 7:00PM CDT
Big money managers are once again shifting direction, Cramer says.
Vertex ends hepatitis C investment as sales fall
AP - Thu May 01, 6:27PM CDT
NEW YORK (AP) — Vertex Pharmaceuticals, which reported more than $1 billion in sales of its hepatitis C drug Incivek in 2012, said Thursday it won't invest any more money on research and development of new treatments for the disease.
Final Glance: Biotechnology companies
AP - Thu May 01, 5:07PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
OncoGenex Posts Wider Loss, Beats Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 4:20PM CDT
OncoGenex (OGXI) reported a loss of 59 cents/share in 1Q14, wider than the Zacks Consensus Estimate of a loss of 44 cents and the year-ago loss of 46 cents.
Synageva's Q1 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 4:10PM CDT
Synageva (GEVA) posts narrower-than-expected loss in the first quarter of 2014.
CRL for The Medicines Co.'s Cangrelor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:05PM CDT
The FDA issued a CRL to The Medicines Co.'s (MDCO) NDA for cangrelor.
Midday Glance: Biotechnology companies
AP - Thu May 01, 12:46PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Merck (MRK) Earnings Beat Puts Healthcare ETFs in Focus - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu May 01, 12:34PM CDT
These health care ETFs are in focus thanks to a solid earnings report from Merck (MRK).
United Therapeutics Gains on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 12:10PM CDT
United Therapeutics' (UTHR) first quarter earnings were significantly above expectations.
Wider-than-expected Loss at Alkermes, Revenues Slip - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 10:50AM CDT
Lower revenues primarily led to the wider loss at Alkermes (ALKS).
Watch for Shares of Gilead Sciences (GILD) to Approach Resistance at $80.73
Comtex SmarTrend(R) - Thu May 01, 10:15AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $77.55 today and have reached the first resistance level of $79.61. Analysts will be watching for a cross of the next upside pivot targets of $80.73 and $83.91.
Early Glance: Biotechnology companies
AP - Thu May 01, 10:09AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Strength Seen in Avanir Pharmaceuticals, Inc. (AVNR) as Stock Shoots up 45.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 7:44AM CDT
Avanir Pharmaceuticals, Inc. (AVNR) was a big mover last session, as the company saw its shares surge a whopping 45.6% on the day.
Kors Among 5 Stocks With Superior 3-Year EPS Growth
at Investor's Business Daily - Thu May 01, 7:02AM CDT
Fundamentally sound stocks such as Michael Kors have demonstrated long-term stability. With the market in correction, they're good candidates for a stock watch list. Today's Screen Of The Day is Top Fundamentals, stocks with three-year earnings per...
Beyond Bristol's Big Dividend: 3 Things Investors Need to Know
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 5:30PM CDT
Bristol-Myers ' first-quarter sales appear tepid at best as revenue fell 1% to $3.8 billion, although its juicy dividend of 2.9% has certainly been attractive to income investors.However, there are some encouraging signs that Bristol may be...
Gilead Sciences Rises 2.95% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 30, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $75.49 to a high of $78.67. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $76.80 on volume of 20.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 2.95% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Apr 30, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $75.49 to a high of $78.67. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $76.80 on volume of 20.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Amicus Up on Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 1:32PM CDT
Shares of Amicus Therapeutics (FOLD) shot up 20.7% after it announced positive data from its first phase III study on migalastat HCl monotherapy.
